NASDAQ:OCX OncoCyte (OCX) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free OCX Stock Alerts $2.98 -0.02 (-0.67%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$2.96▼$2.9850-Day Range$2.85▼$3.3552-Week Range$2.08▼$7.40Volume1,766 shsAverage Volume11,353 shsMarket Capitalization$24.61 millionP/E RatioN/ADividend YieldN/APrice Target$3.87 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get OncoCyte alerts: Email Address OncoCyte MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside29.8% Upside$3.87 Price TargetShort InterestBearish2.35% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.93Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.58) to ($2.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.46 out of 5 starsMedical Sector849th out of 939 stocksDiagnostic Substances Industry12th out of 13 stocks 3.3 Analyst's Opinion Consensus RatingOncoCyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.87, OncoCyte has a forecasted upside of 29.8% from its current price of $2.98.Amount of Analyst CoverageOncoCyte has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted2.35% of the float of OncoCyte has been sold short.Short Interest Ratio / Days to CoverOncoCyte has a short interest ratio ("days to cover") of 13.5, which indicates bearish sentiment.Change versus previous monthShort interest in OncoCyte has recently increased by 0.39%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldOncoCyte does not currently pay a dividend.Dividend GrowthOncoCyte does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OCX. Previous Next 3.3 News and Social Media Coverage News SentimentOncoCyte has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for OncoCyte this week, compared to 1 article on an average week.MarketBeat Follows1 people have added OncoCyte to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OncoCyte insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.94% of the stock of OncoCyte is held by insiders.Percentage Held by Institutions55.35% of the stock of OncoCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for OncoCyte are expected to decrease in the coming year, from ($1.58) to ($2.91) per share.Price to Book Value per Share RatioOncoCyte has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaTop Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024. About OncoCyte Stock (NASDAQ:OCX)OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.Read More OCX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OCX Stock News HeadlinesMarch 25, 2024 | americanbankingnews.comOncoCyte (NASDAQ:OCX) Now Covered by StockNews.comMarch 19, 2024 | americanbankingnews.comStockNews.com Begins Coverage on OncoCyte (NASDAQ:OCX)March 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.February 29, 2024 | msn.comNeuroBo stock jumps 14% on weight-loss drug updateFebruary 24, 2024 | benzinga.comOncoCyte Stock (NASDAQ:OCX), Short Interest ReportJanuary 16, 2024 | finance.yahoo.comOncocyte to Present at the Sequire Investor Summit in Puerto RicoJanuary 7, 2024 | markets.businessinsider.comBTIG Reaffirms Their Hold Rating on OncoCyte (OCX)December 11, 2023 | benzinga.comOncoCyte Stock (NASDAQ:OCX) Dividends: History, Yield and DatesMarch 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.December 6, 2023 | finance.yahoo.comOncocyte Begins FDA Submissions Process for VitaGraft Transplant AssaysNovember 18, 2023 | morningstar.comOncoCyte Corp OCXNovember 10, 2023 | finance.yahoo.comOncoCyte Corporation (NASDAQ:OCX) Q3 2023 Earnings Call TranscriptNovember 9, 2023 | finance.yahoo.comOncoCyte Corp (OCX) Reports Q3 2023 Financial Results with Key Product Launches on the HorizonNovember 9, 2023 | finance.yahoo.comOncocyte Reports Third Quarter 2023 Financial ResultsNovember 3, 2023 | finance.yahoo.comOncocyte to Announce Third Quarter 2023 Financial ResultsSeptember 18, 2023 | finanznachrichten.deOncocyte Corporation: Oncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months EarlierSeptember 18, 2023 | finance.yahoo.comOncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months EarlierSeptember 6, 2023 | finance.yahoo.comOncocyte to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 28, 2023 | finanznachrichten.deOncocyte Corporation: Oncocyte's VitaGraft Kidney Transplant Diagnostic Test Receives CMS CoverageAugust 28, 2023 | finance.yahoo.comOncocyte's VitaGraft Kidney Transplant Diagnostic Test Receives CMS CoverageAugust 24, 2023 | nasdaq.comBenchmark Maintains Oncocyte (OCX) Speculative Buy RecommendationAugust 15, 2023 | msn.comPiper Sandler Maintains Oncocyte (OCX) Neutral RecommendationAugust 11, 2023 | msn.comNeedham Maintains Oncocyte (OCX) Buy RecommendationAugust 10, 2023 | finanznachrichten.deOncocyte Corporation: Oncocyte Reports Second Quarter 2023 Financial ResultsAugust 10, 2023 | finance.yahoo.comOncocyte Reports Second Quarter 2023 Financial ResultsAugust 9, 2023 | finance.yahoo.comOncocyte Regains Compliance With Nasdaq Listing RequirementsAugust 9, 2023 | finanznachrichten.deOncocyte Corporation: Oncocyte Regains Compliance With Nasdaq Listing RequirementsSee More Headlines Receive OCX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today3/28/2024Next Earnings (Estimated)3/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolNASDAQ:OCX CUSIPN/A CIK1642380 Weboncocyte.com Phone(949) 409-7600Fax510-521-3389Employees75Year FoundedN/APrice Target and Rating Average Stock Price Target$3.87 High Stock Price Target$5.00 Low Stock Price Target$3.00 Potential Upside/Downside+29.8%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-72,900,000.00 Net Margins-3,923.58% Pretax Margin-1,427.20% Return on Equity-77.26% Return on Assets-33.66% Debt Debt-to-Equity RatioN/A Current Ratio2.11 Quick Ratio2.11 Sales & Book Value Annual Sales$960,000.00 Price / Sales25.64 Cash Flow$0.88 per share Price / Cash Flow3.38 Book Value$5.78 per share Price / Book0.52Miscellaneous Outstanding Shares8,260,000Free Float8,101,000Market Cap$24.61 million OptionableNo Data Beta0.80 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Joshua Riggs (Age 41)President, CEO & Director Comp: $373.2kMr. James Liu (Age 28)Senior Director, Controller, Principal Accounting Officer & Interim Principal Financial Officer Comp: $192.48kDr. Ekkehard Schutz M.D.Ph.D., Chief Science OfficerMr. Peter HongVP, General Counsel & SecretaryMr. Yuh-Min Chiang Ph.D.Senior Vice President of R&D and Product DevelopmentMs. Sandra O'DonaldSenior Vice President of Business OperationsDr. Michael D. West Ph.D. (Age 71)Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc. Ms. Sara RiordanDirector of Medical EducationMore ExecutivesKey CompetitorsARCA biopharmaNASDAQ:ABIOCardio DiagnosticsNASDAQ:CDIOTrinity BiotechNASDAQ:TRIBBiomericaNASDAQ:BMRAAspira Women's HealthNASDAQ:AWHView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 7,784 shares on 3/11/2024Ownership: 3.001%Vanguard Group Inc.Bought 7,784 shares on 2/15/2024Ownership: 3.001%Pura Vida Investments LLCSold 71,191 shares on 2/13/2024Ownership: 7.106%Defender Capital LLC.Sold 42,870 shares on 1/23/2024Ownership: 0.867%Alfred D KingsleyBought 1,500 shares on 6/14/2023Total: $6,300.00 ($4.20/share)View All Insider TransactionsView All Institutional Transactions OCX Stock Analysis - Frequently Asked Questions Should I buy or sell OncoCyte stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" OCX shares. View OCX analyst ratings or view top-rated stocks. What is OncoCyte's stock price target for 2024? 3 analysts have issued 12-month price objectives for OncoCyte's stock. Their OCX share price targets range from $3.00 to $5.00. On average, they expect the company's stock price to reach $3.87 in the next year. This suggests a possible upside of 29.8% from the stock's current price. View analysts price targets for OCX or view top-rated stocks among Wall Street analysts. How have OCX shares performed in 2024? OncoCyte's stock was trading at $2.50 at the beginning of the year. Since then, OCX stock has increased by 19.2% and is now trading at $2.98. View the best growth stocks for 2024 here. When is OncoCyte's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024. View our OCX earnings forecast. How were OncoCyte's earnings last quarter? OncoCyte Co. (NASDAQ:OCX) released its earnings results on Tuesday, November, 9th. The company reported ($3.00) earnings per share for the quarter, missing the consensus estimate of ($2.40) by $0.60. The firm had revenue of $0.98 million for the quarter, compared to analysts' expectations of $3.20 million. OncoCyte had a negative net margin of 3,923.58% and a negative trailing twelve-month return on equity of 77.26%. When did OncoCyte's stock split? Shares of OncoCyte reverse split before market open on Tuesday, July 25th 2023. The 1-20 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of OncoCyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include VBI Vaccines (VBIV), Biocept (BIOC), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC), Xeris Biopharma (XERS), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), Acasti Pharma (ACST) and Aileron Therapeutics (ALRN). Who are OncoCyte's major shareholders? OncoCyte's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Pura Vida Investments LLC (7.11%), Vanguard Group Inc. (3.00%), Vanguard Group Inc. (3.00%), Defender Capital LLC. (0.87%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alfred D Kingsley, Andrew J Last, Broadwood Partners, LP, Cavan M Redmond, Douglas T Ross, Gisela Paulsen, Li Yu, Pura Vida Investments, Llc and Ronald Asbury Andrews. View institutional ownership trends. How do I buy shares of OncoCyte? Shares of OCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OCX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoCyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.